PB1849: TRIAL IN PROGRESS: PHASE IB/II STUDY OF SIREMADLIN IN COMBINATION WITH VENETOCLAX + AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY

• N. G. Daver,
• A. H. Wei,
• E. M. Stein,
• D. J. DeAngelo,
• D. Pathak,
• Y. Xu,
• S. Grzesiak,
• A. Venditti

Affiliations

N. G. Daver

1 Department of Leukemia, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, United States of America

A. H. Wei

2 Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia

E. M. Stein

3 Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York

D. J. DeAngelo

4 Dana-Farber Cancer Institute, Boston, United States of America

D. Pathak

5 Novartis Pharmaceuticals AG, Basel, Switzerland

Y. Xu

6 Novartis Pharmaceuticals Corporation, East Hanover, United States of America

S. Grzesiak

5 Novartis Pharmaceuticals AG, Basel, Switzerland

A. Venditti

7 Hematology, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy